Merck (MRK.XE) said on Wednesday that it has signed a memorandum of understanding with Samsung Biologics (207940.SE) that extends an agreement to supply raw materials for biopharmaceutical manufacturing.
Under the agreement, Merck's life-science business MilliporeSigma will provide single-use equipment, as well as cell line, cell culture media and chromatography to Samsung Biologics to help accelerate biologics development.
Continue Reading Below
Samsung's biopharmaceutical arm and the German pharmaceutical company had already signed a supply agreement for raw materials in 2014.
Write to Euan Conley at firstname.lastname@example.org
(END) Dow Jones Newswires
November 01, 2017 03:19 ET (07:19 GMT)